Ultragenyx Pharmaceutical (RARE) Projected to Release Quarterly Earnings on Tuesday

Ultragenyx Pharmaceutical (NASDAQ:RARE) is projected to post its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Ultragenyx Pharmaceutical to announce earnings of ($1.2116) per share and revenue of $183.0770 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 5:00 PM ET.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The firm had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. During the same period in the prior year, the company posted ($1.57) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was down 2.2% compared to the same quarter last year. On average, analysts expect Ultragenyx Pharmaceutical to post $-5 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Ultragenyx Pharmaceutical Trading Down 0.0%

NASDAQ:RARE opened at $26.89 on Tuesday. The stock has a market capitalization of $2.65 billion, a P/E ratio of -4.40 and a beta of 0.31. Ultragenyx Pharmaceutical has a 1 year low of $18.29 and a 1 year high of $39.89. The firm has a 50 day moving average of $27.50 and a 200-day moving average of $24.68.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 4,683 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $24.90, for a total value of $116,606.70. Following the transaction, the chief financial officer directly owned 110,342 shares in the company, valued at approximately $2,747,515.80. This trade represents a 4.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the sale, the executive vice president directly owned 94,462 shares of the company’s stock, valued at $2,325,654.44. This trade represents a 1.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 19,319 shares of company stock worth $476,837. Company insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently made changes to their positions in RARE. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical in the third quarter worth about $39,000. Aster Capital Management DIFC Ltd bought a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth about $56,000. Smartleaf Asset Management LLC lifted its position in Ultragenyx Pharmaceutical by 43.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 751 shares during the period. Empowered Funds LLC acquired a new position in Ultragenyx Pharmaceutical during the 4th quarter valued at about $66,000. Finally, Van ECK Associates Corp boosted its stake in shares of Ultragenyx Pharmaceutical by 26.1% in the 3rd quarter. Van ECK Associates Corp now owns 2,650 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 549 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on RARE shares. Barclays decreased their target price on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, April 29th. Wedbush cut their price target on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Royal Bank Of Canada upped their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Guggenheim reduced their price target on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Finally, Morgan Stanley increased their price objective on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, April 16th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $58.41.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.